Top

Gepubliceerd in:

2015 | OriginalPaper | Hoofdstuk

Medicamenteuze preventie en behandeling van atherotrombose

Auteur : Prof. dr. F. W. A. Verheugt

Uitgeverij: Bohn Stafleu van Loghum

Abstract

De pathofysiologie van atherotrombose is altijd terug te voeren op atherosclerose. Het natuurlijk beloop van atherosclerose is goedaardig, tenzij zich plotselinge stroomveranderingen over de stenosen voordoen. In het ergste geval raakt een vernauwd vat plotseling geheel afgesloten, waardoor het achterliggend weefsel langdurig ischemisch wordt en afsterft: het infarct. Als deze plotselinge vormen van ischemie niet kunnen worden opgevangen door collateralisatie, zal een dergelijk infarct groot zijn, met alle gevolgen van dien: pompfunctiestoornissen, maligne kamerritmestoornissen, een invaliderend of fataal herseninfarct, of een afstervend ledemaat.

Verheugt FWA. De morgenstond heeft onheil in de mond: circadiane variatie in bloedstolbaarheid en cardiovasculaire gebeurtenissen. Ned Tijdschr Geneeskd 1993;137:1184–7.PubMed

Verheugt FWA, Brugada P. Sudden death after myocardial infarction: the forgotten thrombotic view. Am J Cardiol 1991;67:1130–4.PubMedCrossRef

Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995;49:856–84.PubMedCrossRef

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.CrossRef

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;349:1329–39.

CURE Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.CrossRef

Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33.PubMedCrossRef

Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957–66.PubMedCrossRef

Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized trials. Lancet 2002;359:189–98.PubMedCrossRef

10.

Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina pectoris: a meta-analysis. JAMA 1996:276:811–5.PubMedCrossRef

11.

Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004;292:89–96.PubMedCrossRef

12.

Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menowa IB, Yusuf S Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a metaanalysis of the randomized trials. Circulation 2006;112:3855–67.CrossRef

13.

Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of Fondaparinux, a factor Xa inhibitor, on mortality and reinfarction in patients with acute myocardial infarction presenting with ST-segment elevation. Organization to Assess Strategies for Ischemic Syndromes (OASIS)-6 Investigators. JAMA 2006;295:1519–30.PubMedCrossRef

14.

OASIS-5 investigators. Comparison of fondaparinux and enoxaprin in acute coronary syndromes. N Engl J Med 2006;354;1464–76.CrossRef

15.

Brouwer MA, Van den Bergh PJPC, Vromans RPJW, et al. Aspirin plus medium intensity coumadin versus aspirin alone in the prevention of reocclusion after successful thrombolysis for suspected acute myocardial infarction: results of the APRICOT-2 study. Circulation 2002;106:659–65.PubMedCrossRef

16.

Van Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109–13.PubMedCrossRef

17.

Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;379:969–74.PubMedCrossRef

18.

Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist clinic: a randomised cross-over comparison. Lancet 2000;356:97–102.PubMedCrossRef

19.

Verheugt FWA. Can we pull the plug for warfarin in atrial fibrillation? Lancet 2003;362:1686–7.PubMedCrossRef

20.

Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789–97.PubMedCrossRef

Titel: Medicamenteuze preventie en behandeling van atherotrombose
Auteur: Prof. dr. F. W. A. Verheugt
Uitgeverij: Bohn Stafleu van Loghum
DOI: https://doi.org/10.1007/978-90-313-6597-5_6

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen